Dr. Reddys Lab - Significant Growth In Overall Performance: Dolat Capital

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Dr. Reddy’s Laboratories Ltd.'s FY24 annual report analysis suggests significant growth in overall performance. Consolidated revenue from operations increased by 13.5% to Rs 280.1 billion from Rs 246.7 billion in FY23.

Ebitda also increased substantially by 23.6% to Rs 79.3 billion from Rs 64.2 billion in FY23, while profit after tax came in at Rs 55.7 billion from Rs 45.1 billion in FY23. While the company operates across multiple businesses including API s, generics, branded generics, biosimilars and over -the -counter pharma products around the world , growth will be driven by-

investments in consumer health,
digital health solutions, and
access to novel molecules.

Click on the attachment to read the full report:

Dolat Capital Dr. Reddys Laboratories_ARA_FY24.pdf

Read Document

Also Read: Internet Q1 Results Preview: B2C Growth Momentum Sustaining, B2B Picking Up: ICICI Securities

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.